EVALUATION HYPOLIPIDEMIC ACTIVITY OF AROGYAVARDHINI AND ZPTER TABLET IN CHOLESTEROL-RICH HIGH FAT DIET (HFD) INDUCED HYPERLIPIDEMIA IN WISTAR RATS

Objective: The present research work aims to evaluate the hypolipidemic activity of arogyavardhini and zpter tablet in high fat diet (HFD) induced hyperlipidemia in wistar rats. Methods: Wistar rats were divided in 5 groups. The normal control group received standard pellet diet. The HFD group received HFD rich in cholesterol. The HFD+Arogyavardhini group received HFD rich in cholesterol along with Arogyavardhini treatment. The HFD+zpter group received HFD rich in cholesterol along with zpter treatment. The standard Control group received HFD rich in cholesterol and treatment with Atorvastatin. Serum Lipid profile estimation and histopathological estimations done at end treatment. Group means were compared with Analysis of Variance (ANOVA) followed by Tukey‘s post-hoc analysis (P<0.05). Result: HFD group shows significant (P<0.05) increase in total cholesterol (TC) levels (207.15 mg/dl) and triglyceride (TG) levels (223.83 mg/dl) when compared with standard pellet fed rats (TC=151.05 mg/dl and TG=164.67 mg/dl). Treatment with Arogyavardhini significantly (P<0.05) reduces the increased levels of TC (160.123 mg/dl) and TG (189.5 mg/dl) in hyperlipedimic rats. Treatment with Zpter significantly (P<0.05) reduces the increased levels of TC (163.89 mg/dl) and TG (193.167 mg/dl) in hyperlipedimic rats, which is comparable to standard treatment atorvastatin (TC= 155.81 mg/dl, TG=180.33 mg/dl). Conclusion: The observations in this study suggest that, herbal formulations arogyavardhini and zpter have the potential to overcome hyperlipidemia

Characterization of Copper-based Ayurved Medicine Tamra bhasma produced by various manufacturers and its Pharmacokinetic profiling in Wistar rat

Background: Tamra bhasma (TB) is copper based herbo-metallic preparation which is used extensively by Ayurvedic practitioners. Tamra bhasma is endorsed for different disorders of liver, abdominal pain, heart disease, colitis, tumors, anemia, loss of appetite, tuberculosis, as well as eye problems. Objective: Our aim is to characterize 5 commercial TB preparations from 5 different manufacturers by using modern scientific techniques and to study there bioavailability in Wistar rats. Materials and Methods: Tamra bhasma was characterized by X-ray diffraction (XRD), Scanning electron microscope (SEM), Energy Dispersive X-ray analysis (EDAX), Nanoparticle tracking analyzer (NTA), Inductively coupled plasma optical emission spectroscopy (ICP-OES). Bioavailability of Tamra bhasma was studies using non compartmental rat model with daily dose of 6.45mg/kg according to their body weight. Results: The colour of one of the TB preparation was different from other 4 TB samples. The chemical phase and particle size is significantly different for all the 5 TB’s. Pharmacokinetic model confirms difference in various PK parameters such as peak concentration (Cmax), half-life (t1/2) and terminal elimination slope (λz) for all 5 TB’s. TB-A showed highest Cmax (82.21 mg/L), whereas TB-E showed lowest Cmax (48.69 mg/L). The highest bioavailability of TB is may be due to specific chemical moiety and morphology. Based on XRD and elemental analysis, it was found that manufacturing route followed for one of the preparation is not as per ayurvedic text reference. Conclusions: The morphology as well as chemical phase of the five TB’s studied were different from each other, which might be responsible for different pharmacokinetic profiles in Wistar rat model

Efficacy and Safety Evaluation of Myostaal Forte, a Polyherbal Formulation, in Treatment of Knee Osteoarthritis: A Randomised Controlled Pilot Study

Introduction: Myostaal Forte, a proprietary poly-herbal formulation, is mixture of nine herbal plant extracts which possess analgesic, anti-inflammatory and chondroprotective properties. Aim: A prospective, randomised, active controlled, 2-arm, parallel group, assessor blind study was planned to evaluate clinical efficacy and safety of Myostaal Forte in patients of knee osteoarthritis. Materials and Methods: Idiopathic knee osteoarthritis cases as per American College of Rheumatology (ACR) clinical criteria were screened and recruited. A total of sixty patients were assigned to receive Myostaal Forte TDS (n=30) or Paracetamol 650 mg TDS (n=30) for six weeks. Naproxen was rescue analgesia. Modified Western Ontario and McMaster Universities Arthritis Index (WOMAC), Visual Analogue Scale (VAS), global assessment scores determined by orthopaedic physician at baseline, two, four, six weeks and telephonically at eight weeks. Safety was assessed through laboratory investigations at baseline and six weeks, adverse events and tolerability. Data were expressed as Mean±SD and analysed by Chi-square and unpaired t-test. p<0.05 was considered significant. Results: Myostaal Forte and Paracetamol showed significant reduction in osteoarthritis disease activity. Myostaal Forte produced significant improvement compared to Paracetamol, in the pain, stiffness and physical function from baseline to eight weeks (p0.05). No significant adverse events, changes in the laboratory parameters and excellent compliance to treatment were seen in both the groups. Conclusion: Earlier onset analgesic effect with sustained chondroprotection after treatment cessation makes Myostaal Forte, a safe and effective alternative for treatment of knee osteoarthritis